Comply with new prices of 137 anti-cancer drugs or face action, says regulator

The National Pharmaceutical Pricing Authority (NPPA) has mandated compliance with new price caps on 137 anti-cancer drugs, threatening penal action for violations. Manufacturers and retailers must display these updated prices to ensure patients benefit from the reduced costs.
Why it matters
Price regulation of essential medicines is vital for improving healthcare affordability and accessibility for the public.
NEW DELHI The National Pharmaceutical Pricing Authority (NPPA) has warned of penal action against those failing to comply with the revised prices of 137 non-scheduled anti-cancer drugs The authority, which functions under the Department of Pharmaceuticals, has asked State drug controllers (SDCs) to strictly monitor the prices and submit their action taken reports by November 16, according to an official release on Friday (November 13, 2026). The revised prices for the 137 anti-cancer drugs came into effect on November 9, 2026, following a gazette order issued on October 17, 2026. The order capped the trade margin on these medicines at 30%.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in